Research graph
References from Fluorine-18 labeled PI-2620 tau positron emission tomography and quantitative susceptibility mapping reveal spatiotemporal interactions between tau deposition and iron accumulation in progressive supranuclear palsy. Local targets link to admitted publications; unresolved targets remain external evidence.
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
10.1016/s1474-4422(17)30157-6 · 2017 · External reference
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
10.1002/mds.26987 · 2017 · External reference
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies
10.1007/s00259-019-04397-2 · 2019 · External reference
Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies
10.1093/braincomms/fcab190 · 2021 · External reference
Imaging of tau pathology in neurodegenerative diseases: an update
10.1053/j.semnuclmed.2020.12.004 · 2021 · External reference
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
10.1007/s00259-022-05964-w · 2022 · External reference
Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy
10.1001/jamaneurol.2020.2526 · 2020 · External reference
The irony of iron: the element with diverse influence on neurodegenerative diseases
10.3390/ijms25084269 · 2024 · External reference
Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers
10.1016/j.neuroimage.2020.117433 · 2021 · External reference
Relationship between cortical iron and tau aggregation in Alzheimer's disease
10.1093/brain/awaa089 · 2020 · External reference
Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy
10.1002/mds.24926 · 2012 · External reference
Quantitative susceptibility mapping: basic methods and clinical applications
10.1148/rg.210054 · 2022 · External reference
Brain pathological changes during neurodegenerative diseases and their identification methods: how does QSM perform in detecting this process?
10.1186/s13244-022-01207-6 · 2022 · External reference
Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy
10.1007/s13760-023-02352-5 · 2024 · External reference
Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms
10.1111/ene.15447 · 2022 · External reference
Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy
10.1016/j.neuroimage.2024.120509 · 2024 · External reference
Quantitative susceptibility mapping in atypical parkinsonisms
10.1016/j.nicl.2019.101999 · 2019 · External reference
Distribution patterns of tau pathology in progressive supranuclear palsy
10.1007/s00401-020-02158-2 · 2020 · External reference
Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus
10.1148/radiol.12102273 · 2013 · External reference
Brain iron accumulation in atypical parkinsonian syndromes: in vivo MRI evidences for distinctive patterns
10.3389/fneur.2019.00074 · 2019 · External reference
Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy
1998 · External reference
Contrasting effects of ferric and ferrous ions on oligomerization and droplet formation of tau: implications in tauopathies and neurodegeneration
10.1021/acschemneuro.1c00377 · 2021 · External reference
Perivascular orientation of astrocytic plaques and tuft-shaped astrocytes
10.1016/j.brainres.2011.06.014 · 2011 · External reference
Cell-specific dysregulation of iron and oxygen homeostasis as a novel pathophysiology in PSP
10.1002/ana.26540 · 2023 · External reference
Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy
10.1007/s00401-024-02823-w · 2024 · External reference
Microscopy assessment of a fluorescence [18F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions
10.1002/alz.14330 · 2024 · External reference
Multimodal neuroimaging relationships in progressive supranuclear palsy
10.1016/j.parkreldis.2019.07.001 · 2019 · External reference
Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant
10.1016/j.nicl.2022.103030 · 2022 · External reference
Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy
10.1016/j.parkreldis.2018.02.004 · 2018 · External reference
Track density imaging in progressive supranuclear palsy: a pilot study
10.1002/hbm.24484 · 2019 · External reference
Caudate nucleus as a component of networks controlling behavior
10.1212/wnl.0000000000004680 · 2017 · External reference
Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal
10.1016/j.nicl.2023.103402 · 2023 · External reference
Magnetic susceptibility in progressive supranuclear palsy variants, Parkinson's disease, and corticobasal syndrome
10.1002/mds.29613 · 2023 · External reference
Spatially resolved panoramic in vivo CRISPR screen via perturb-DBiT
2025 · External reference
Spatial dynamics of brain development and neuroinflammation
10.1038/s41586-025-09663-y · 2025 · External reference
